Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Matthew A CavenderRobert A HarringtonGregg W StonePhillippe Gabriel StegC Michael GibsonChristian W HammMatthew J PriceRenato Deláscio LopesSergio LeonardiEfthymios N DeliargyrisJayne PratsKenneth W MahaffeyHarvey D WhiteDeepak L Bhattnull nullPublished in: Circulation. Cardiovascular interventions (2021)
The reductions in ischemic events and overall efficacy seen with cangrelor in CHAMPION PHOENIX occurred early and during the period of time in which patients were being actively treated with cangrelor. These findings provide evidence that supports the importance of potent platelet inhibition during percutaneous coronary intervention. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01156571.
Keyphrases
- percutaneous coronary intervention
- patients undergoing
- st segment elevation myocardial infarction
- end stage renal disease
- acute myocardial infarction
- acute coronary syndrome
- coronary artery disease
- newly diagnosed
- st elevation myocardial infarction
- antiplatelet therapy
- coronary artery bypass grafting
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- atrial fibrillation
- heart failure
- patient reported outcomes
- brain injury
- anti inflammatory